13F Holdings
中文EN

SPRC SciSparc Ltd. IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1611746 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-54.6%
TTM net income YoY-22.7%
TTM EPS YoY-91.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin38.7%
Operating margin-560.2%
Net margin-481.2%
FCF margin—
EBITDA margin-523.3%

Returns

ROE-79.7%
ROA-58.4%
ROIC (approx.)-95.1%
Asset turnover0.12x

Leverage & solvency

Liabilities / assets13.6%
Debt / equity0.00x
Current ratio5.36x
Interest coverage-20.73x

Cash quality & payout

Operating cash flow / net income0.81x
Accruals ratio-11.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31FY20202020-12-31
Income statement
Revenue$1.31M$2.88M$1.35M——
Cost of revenue$800,000$683,000$322,000——
Gross profit$506,000$2.20M$1.02M——
R&D expense$1.71M$1.64M$2.80M$1.99M$649,000
SG&A expense$4.53M$3.84M$5.43M$3.78M$1.90M
Operating income-$7.32M-$6.82M-$8.29M-$5.77M-$3.29M
Interest expense$353,000$1.05M$2.01M$21,000$872,000
Pretax income-$7.49M-$5.86M-$2.58M-$5.79M-$3.54M
Income tax-$14,000$22,000$14,000——
Net income-$6.28M-$5.12M-$2.59M-$5.79M$3.54M
EBITDA-$6.83M-$6.28M-$8.10M-$5.74M-$3.13M
EPS (basic)1.2814.4314.8273.580.10
EPS (diluted)1.2814.4314.8273.580.11
Weighted avg. shares (diluted)5.82M407,681175,95379,000—
Banking
Net interest income-$259,000-$1.16M-$5.82M$21,000$242,000
Balance sheet
Cash & equivalents$1.54M$2.08M$3.57M$6.88M$1.95M
Receivables$10,000$22,000$77,000$2.90M$594,000
Inventory$113,000$742,000$668,000——
Current assets$7.50M$6.45M$4.51M$9.82M$2.55M
PP&E, netmay include right-of-use assets (IFRS)$59,000$108,000$57,000$92,000$11,000
Intangibles$1.48M$3.19M$4.72M——
Total assets$10.35M$11.18M$10.61M$9.92M$2.56M
Current liabilities$1.40M$1.57M$4.16M$1.76M$1.13M
Short-term debt————$188,000
Total liabilities$1.41M$1.59M$4.16M$1.77M$1.13M
Shareholders' equity$8.15M$7.61M$6.45M$8.14M$1.43M
Shares outstanding515,64033,652261,4943.09M1.04M
Cash flow statement
Operating cash flow-$5.10M-$5.89M-$7.92M-$5.06M-$4.31M
Capital expenditure——$8,000$35,000—
Free cash flow——-$7.92M-$5.10M—
Investing cash flow-$1.62M-$4.09M-$7.08M-$70,000$24,000
Financing cash flow$6.19M$8.48M$11.70M$10.06M$5.36M
Depreciation & amortization$482,000$538,000$187,000$33,000$164,000
Stock-based compensation$569,000$196,000$897,000$43,000$91,000

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.